Compare Stanley Black & Decker, Inc. (SWK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Viatris Inc — how do they compare? Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.77%). Which is the better fit depends on your goals — on Pluang, investors hold Stanley Black & Decker, Inc. for 62 Days and Viatris Inc for 57 Days on average.
| SWK | VTRS | |
|---|---|---|
Market Cap | $13.47B | $20.03B |
Volume | 2,859,744 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $104.00 | $18.27 |
52-Week Low | $62.12 | $9.74 |
Typical Hold Time | 62 Days | 57 Days |
Enterprise Value | $17.63B | $32.15B |
Dividend Yield | 3.77% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $89.17, showing modest daily gains of 0.97%. The stock exhibits bearish technical signals with neutral oscillators, while fundamentals show improving profitability with three consecutive quarterly earnings beats. Recent product launches and margin improvement initiatives support growth prospects, though cash flow trends remain mixed. The company maintains Dividend King status with over 200 years of dividend payments.
SWK presents a balanced opportunity with improving earnings momentum and attractive valuation metrics, though technical weakness and margin pressures warrant caution. Analyst consensus leans neutral with a $93 price target suggesting limited upside. Key risks include execution challenges in margin improvement and competitive pressures in the tools market.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
